Champions Oncology Inc 2024年度报告

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).Yes¨Noþ The number of shares of common stock of the Registrant outstanding as of July 21, 2025 was13,777,170.DOCUMENTS INCORPORATED BY REFERENCE DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, andSection 21E of the Securities Exchange Act of 1934, as amended, (the "Exchange Act") that inherently involve risk and uncertainties.Forward-looking statements may be identified by the words “project,” “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “should,” “would,”“could,” “will,” “may,” “likely” or similar expressions. Forward-looking statements in this Annual Report include statements about ourbusiness strategies and products development activities, including the anticipated benefits and risks associated with those strategies as well asstatements about the sufficiency of our capital resources.One should not place undue reliance on these forward-looking statements.We cannotguarantee that we will achieve the plans, intentions or expectations expressed or implied in our forward-looking statement.There are a numberof important factors that could cause actual results, levels of activity, performance or events to differ materially from those expressed or impliedin the forward-looking statements we make.These important factors are described under “Risk Factors” set forth below.In addition, anyforward-looking statements we make in this Annual Report speak only as of the date of this document, and we do not intend to update any such We are a technology-enabled research organization engaged in creating technology solutions to be utilized in drug discovery and development. Our research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set ofcomputational and experimental research platforms. Our pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. At the core of our research platforms is our unique, proprietary bank of Patient Derived Xenograft (PDX) models. This preeminent bank ofPDX models is deployed into advanced in vivo and ex vivo pharmacology platforms, providing an enhanced level of insight into therapeuticprograms.We currently have approximately 1,500 PDX Models in our TumorBank that we believe reflect the characteristics of patients whoenroll in clinical trials (late stage, pretreated and metastatic). This characteristic of our TumorBank is an important differentiator to other The PDX bank is highly characterized at the molecular, phenotypic and pharmacological levels, which provides a differentiated layer of datafor our large oncology dataset (the "Datacenter").The Datacenter combines our proprietary dataset with other large publicly available datasets.This dataset currently includes approximately 3,500 molecular datasets (genomics, transcriptomics, proteomics, phosphor-proteomics),approximately 3,000 clinical drug responses, approximately 3,500 in vivo drug responses, and the accompanying clinical information on thepatients from which they were derived (pre and post tumor sample acquisition of drug treatments and responses, age, gender, ethnicity, tumor transcriptomics, proteomics, and functional genomics, and patient outcome. This Datacenter facilitates our computational approach to drugdiscovery and provides the foundation to our Software as a Service ("SaaS") offerings. Collectively, our computational and experimentalresearch platforms enable a more rapid and precise approach to drug discovery and development.Through our technology platforms, we have designed an ecosystem of business lines consisting of:The sale of research services utilizing our innovative research platforms to biopharmaceutical companiesThe sale of PDX model data and oncology research SaaS tools to cancer research scientistsThe discovery and development of novel oncology therapeutics Research Services Our research services utilize our research center to assist pharmaceutical and biotechnology companies with their drug development process.We perform studies which we believe may predict the efficacy of experimental oncology drugs or approved drugs as stand-alone therapies or incombination with other drugs and can simulate the results of human clinical trials. These studies include in vivo studies that rely on implanting populations for clinical evaluation, identify potential therapeutic combination strategies, and develop biomarker hypothesis of sensitivity orresistance. These studies include the use of our in vivo, ex vivo, analytical and computational platforms. Increasing the breadth of the TumorBank is an important strategic eff